**US84833T1034 - Common Stock **

We assign a fundamental rating of **2** out of 10 to **SPRO**. **SPRO** was compared to 631 industry peers in the **Biotechnology** industry. **SPRO** has a bad profitability rating. Also its financial health evaluation is rather negative. **SPRO** is valued expensive and it does not seem to be growing.

ROA (-158.86%) VS Industry: 9% outperformed.

-950.38

52.28

Profit Margin (-1162.35%) VS Industry: 32% outperformed.

-1,173,705.71

34,743.00

With a price book ratio of **3.04**, **SPRO** is valued correctly.

Besides the negative Price/Earnings Ratio, also the **Forward Price/Earnings Ratio** is negative for **SPRO**. No positive earnings are expected for the next year.

When comparing the price book ratio of **SPRO** to the average industry price book ratio of 1.69, **SPRO** is valued more expensive than its industry peers.

Price/Book (3.04) VS Industry: 29% outperformed.

131.89

0.10

Based on estimates for the next 5 years, **SPRO** will show a small growth in **Earnings Per Share**. The EPS will grow by **5.13%** on average per year.

Based on estimates for the next 5 years, **SPRO** will show a very negative growth in **Revenue**. The Revenue will decrease by **-22.91%** on average per year.

The Revenue growth is decreasing: in the next 5 years the growth will be less than in the last years.

Past | Future | ||||||
---|---|---|---|---|---|---|---|

5Y | 3Y | 1Y | 1Y | 2Y | 3Y | 5Y | |

EPS | N/A | N/A | -16.48% | 14.06% | 21.09% | 7.67% | 5.13% |

Revenue | 121.81% | 66.29% | -49.42% | -45.72% | -47.51% | -29.49% | -22.91% |

A Quick Ratio of **3.26** indicates that **SPRO** has no problem at all paying its short term obligations.

The Debt to Equity ratio of **SPRO** is in line with the industry averages.

When comparing the Current Ratio of **SPRO** to the average industry Current Ratio of **6.16**, **SPRO** is less able to pay its short term obligations than its industry peers.

When comparing the Quick Ratio of **SPRO** to the average industry Current Ratio of **6.05**, **SPRO** is less able to pay its short term obligations than its industry peers.

When comparing the Altman-Z score of **SPRO** to the average industry Altman-Z score of **-0.81**, **SPRO** is less financially healthy than its industry peers. **85%** of its industry peers have a better Altman-Z score.

Debt/Equity (0) VS Industry: 42% outperformed.

15.37

0.00

Quick Ratio (3.26) VS Industry: 28% outperformed.

0.02

84.53

Current Ratio (3.26) VS Industry: 27% outperformed.

0.02

85.09

Altman-Z (-11.17) VS Industry: 15% outperformed.

-135.10

443.02

No dividends for **SPRO**!.

NASDAQ:SPRO (12/1/2022, 10:44:18 AM)**-0.03 (-1.8%) **

GICS Sector | Health Care | ||

GICS IndustryGroup | Pharmaceuticals, Biotechnology & Life Sciences | ||

GICS Industry | Biotechnology | ||

Earnings (Last) | 11-14 2022-11-14/amc | Earnings (Next) | 03-29 2023-03-29 |

Ins Owners | 1.77% | Inst Owners | 38.4% |

Market Cap | 98.63M | Analysts | 80 |

PE | N/A | Fwd PE | N/A |

PEG (NY) | N/A | PEG (5Y) | N/A |

P/S | 11.19 | P/B | 3.04 |

EV/EBITDA | -0.6 |

Dividend Yield | N/A | Dividend Growth | N/A |

DP | N/A | Ex-Date | N/A |

EPS 1Y | -16.48% | EPS 3Y | N/A |

EPS 5Y | N/A | EPS growth Q2Q | 52.86% |

EPS Next Y | 14.06% | EPS Next 2Y | 21.09% |

EPS Next 3Y | 7.67% | EPS Next 5Y | 5.13% |

Revenue growth 1Y | -49.42% | Revenue growth 3Y | 66.29% |

Revenue growth 5Y | 121.81% | Revenue growth Q2Q | -34.53% |

Revenue Next Year | -45.72% | Revenue Next 2Y | -47.51% |

Revenue Next 3Y | -29.49% | Revenue Next 5Y | -22.91% |

Current Ratio | 3.26 | Quick Ratio | 3.26 |

Altman-Z | -11.17 | F-Score | 3 |

Debt/Equity | 0 | WACC | 9.45% |

ROIC/WACC | N/A |

ROA | -158.86% | ROE | N/A |

ROICexgc | N/A | ROIC | N/A |

PM | -1162.35% | OM | -952.41% |

Asset Turnover | 0.14 |

*Find stocks with similar Fundamental rating on the USA*

*Find the competitors with the best fundamentals on the USA*

*Find the competitors with the best valuation on the USA*

*Find the competitors with the best dividend on the USA*